Eli Lilly and Company (NYSE: LLY) reported third-quarter 2026 revenue of $24.40 billion, representing 39% year-on-year growth, as Mounjaro and Zepbound generated combined sales of approximately $16.08 billion. Global sales volumes increased 53%, more than offsetting a 15% decline in realised prices, while reported net income increased 16% to $6.45 billion. The October 29 results prompted the American pharmaceutical manufacturer to raise its annual revenue forecast from $85 billion to $87 billion to a new range of $91 billion to $92 billion. However, the company lowered its non-GAAP earnings per share guidance to $35 to $36 after recognising substantial acquired in-process research and development charges associated with business development activity.
The financial contrast is central to understanding Eli Lilly’s position within the rapidly expanding market for diabetes and obesity treatments. Mounjaro revenue increased 65% to $10.72 billion, while Zepbound grew 49% to $5.35 billion. Together, the two products accounted for approximately 66% of quarterly revenue, demonstrating the commercial importance of tirzepatide across its authorised treatment markets.
Nevertheless, the latest results also reveal the costs of sustaining pharmaceutical leadership. Eli Lilly recognised approximately $4.18 billion in acquired in-process research and development expenditure during the quarter, compared with $656 million a year earlier. The company is also expanding manufacturing capacity and investing in additional obesity, oncology, immunology and neuroscience medicines.
Why did a 53% increase in drug volumes produce only 39% revenue growth for Eli Lilly?
Eli Lilly reported that global sales volumes increased 53% while realised prices declined approximately 15%. The combination demonstrates that substantial additional demand is being partially offset by lower revenue per unit sold. The company’s overall revenue nevertheless increased by approximately $6.8 billion, reflecting the exceptional scale of its commercial expansion.
The pricing decline was particularly pronounced outside the United States, where realised prices fell 29% as volumes increased 76%. Management identified the inclusion of Mounjaro on China’s National Reimbursement Drug List as an important factor. Reimbursement arrangements can expand patient access while reducing the average revenue received by the manufacturer.
Within the United States, volumes increased 41% while realised prices declined 7%. The company attributed the pricing pressure principally to Zepbound, partly offset by adjustments to estimates for rebates and discounts. These figures illustrate the commercial trade-off between expanding access and preserving unit economics.
Lower pricing does not necessarily weaken total profitability when additional volumes generate sufficient gross profit. However, the company must ensure that manufacturing costs, distribution expenses and associated investments remain manageable as patient numbers increase. A strategy built on greater affordability can create substantial revenue opportunities while reducing the contribution from each unit sold.
Investors should therefore evaluate treatment volumes, realised prices and margins together. The latest results demonstrate that demand is strong enough to outweigh pricing pressure today, but the long-term balance will depend on competition, reimbursement arrangements and manufacturing efficiency.
How dependent has Eli Lilly become on Mounjaro and Zepbound for revenue growth?
Mounjaro generated $10.72 billion in worldwide revenue, compared with $6.52 billion a year earlier. Zepbound revenue increased from approximately $3.59 billion to $5.35 billion. The combined contribution of $16.08 billion represents roughly two-thirds of Eli Lilly’s consolidated quarterly sales.
This concentration provides considerable commercial strength because the company has established important positions in diabetes and obesity treatment. However, it also creates exposure to a relatively narrow set of related products and the broader economics of incretin-based therapies. Changes in reimbursement, competition or manufacturing supply could affect a substantial proportion of revenue.
Mounjaro’s international performance was especially strong, with revenue outside the United States increasing 93% to approximately $5.7 billion. US revenue increased 41% to approximately $5 billion. These figures suggest that international market expansion is becoming increasingly important to the franchise.
Zepbound’s US revenue increased approximately 48% to $5.3 billion, demonstrating continued demand despite lower realised prices. However, treatment access and patient affordability remain important factors shaping the commercial market. A product can attract substantial patient interest without every potential user being able to obtain or continue treatment.
Eli Lilly’s investment case therefore depends on sustaining the franchise while developing additional sources of growth. Mounjaro and Zepbound currently provide exceptional scale, but diversification will become increasingly important as the market matures.
Why did Eli Lilly lower its adjusted EPS guidance despite raising revenue expectations by $5.5bn?
Management raised the midpoint of its annual revenue guidance by $5.5 billion to $91.5 billion. It also increased the expected non-GAAP performance margin to between 52% and 52.5%, compared with the previous range of 49% to 50.5%. These changes indicate substantial improvement in the underlying commercial outlook.
However, non-GAAP earnings per share guidance declined to between $35 and $36 from the earlier range of $35.50 to $36.50. The difference is explained by acquired in-process research and development charges rather than a deterioration equivalent to the change in forecast earnings.
Eli Lilly stated that improvements in underlying performance increased the midpoint of expected non-GAAP earnings by approximately $4.07 per share. However, acquired research charges from third-quarter business development activity reduced the outlook by approximately $4.57 per share. The net effect was a $0.50 reduction in the guidance midpoint.
This distinction is important because Lilly’s non-GAAP EPS measure includes acquired in-process research and development expenses. Investors should not assume that every adjusted earnings calculation excludes acquisition-related research expenditure. The company explicitly retains those costs within the measure used for its outlook.
The treatment reflects the significant financial commitments involved in acquiring investigational medicines and research platforms. Such spending can provide future commercial opportunities, but the economic returns remain uncertain until development programmes succeed. The lower EPS outlook therefore reflects a strategic investment decision as well as an accounting consequence.
What do $4.18bn in acquired research charges reveal about Lilly’s expansion strategy?
Eli Lilly recognised approximately $4.18 billion in acquired in-process research and development charges during the quarter. The amount was significantly higher than the $656 million recorded a year earlier and contributed approximately $4.57 per share to the latest earnings calculation. It demonstrates the substantial financial cost of expanding the company’s future medicine portfolio.
The company has been pursuing acquisitions and partnerships across several therapeutic areas. During the quarter, it completed the acquisition of AtaiBeckley, which focuses on therapies for treatment-resistant depression and other mental health conditions. Following the quarter, Eli Lilly also completed its acquisition of Merida Biosciences, expanding its research capabilities in autoimmune and allergic diseases.
These transactions provide access to technologies and development programmes beyond the current obesity and diabetes franchise. However, acquired research assets may still require lengthy clinical testing and regulatory review. A successful transaction depends on the commercial value eventually created rather than the initial research expenditure alone.
The company is also investing in manufacturing expansion in Texas and Virginia. Such projects may improve its ability to support future medicines and respond to demand, but they require substantial capital before production benefits become fully available. Manufacturing investment and acquisitions therefore create different but complementary financial obligations.
The long-term opportunity is to develop additional growth engines that reduce dependence on existing products. The risk is that expensive clinical programmes fail or generate insufficient revenue to justify their acquisition and development costs. Investors should evaluate individual programmes through clinical evidence and prospective commercial economics rather than assuming that a larger research budget guarantees success.
Can Foundayo and retatrutide strengthen Lilly’s position in obesity treatment?
Eli Lilly has expanded its obesity treatment portfolio through the launch of Foundayo, an oral medicine intended to broaden the options available to eligible patients. The product generated approximately $184 million in third-quarter revenue, bringing year-to-date sales to $281 million. These are early commercial figures and should not be interpreted as evidence that the oral product has reached the scale of the established injectable franchise.
Oral treatments may appeal to patients who prefer tablets or face practical difficulties associated with injections. However, adoption depends on efficacy, tolerability, prescribing practices, reimbursement and competition. The commercial value of convenience must be assessed alongside clinical outcomes and total treatment costs.
Retatrutide represents another important development programme. Eli Lilly reported positive results from a head-to-head Phase III study comparing the investigational medicine with Ozempic 2 mg in adults with type 2 diabetes. Such findings may support additional regulatory activity, but trial results do not themselves establish approval or unrestricted clinical availability.
The company continues working across multiple obesity-related clinical programmes, including treatments intended to address different patient requirements. A broader portfolio could improve its ability to serve patients across several treatment settings. Nevertheless, manufacturing capacity, insurance coverage and treatment persistence will influence the commercial opportunity.
Competition from Novo Nordisk and other developers also remains important. Alternative medicines and new treatment formats can affect pricing and market share over time. Eli Lilly must sustain product differentiation while managing the economics of broader access.
Why are oncology, immunology and neuroscience becoming more important to Lilly’s future growth?
Eli Lilly reported that revenue from its designated key products in oncology, immunology and neuroscience doubled during the quarter. The performance suggests that newer medicines beyond diabetes and obesity are becoming more commercially relevant. However, their current combined scale remains substantially below Mounjaro and Zepbound.
Jaypirca sales increased 59% to approximately $228 million, while Ebglyss revenue rose 59% to $202 million. Kisunla generated approximately $193 million, representing a substantial increase from the previous year. These products address different therapeutic areas and have distinct patient populations, regulatory requirements and competitive conditions.
Eli Lilly also reported additional regulatory progress, including expanded indications for selected medicines and approvals involving oncology and diabetes treatment. Each authorisation applies to the patient population and conditions specified in the relevant regulatory decision. Approval should not be interpreted as evidence that a medicine can be used without restriction or that commercial adoption is guaranteed.
Diversification may eventually reduce concentration risk, but the financial returns will depend on the size and profitability of each market. The company must invest in clinical development, manufacturing and commercial activities while competing against established treatments. Not every product will achieve the scale of the leading incretin franchise.
The growth of these businesses nevertheless provides a potentially important second layer of future revenue. Investors should monitor their contribution separately rather than allow exceptional obesity sales to obscure the performance of the wider portfolio.
What should Lilly shareholders watch as the company approaches $92bn in annual revenue?
Eli Lilly’s October results establish a stronger commercial trajectory than management anticipated earlier in the year. Revenue growth, treatment volumes and profitability are improving, while the expanded guidance reflects confidence in demand. However, the financial benefits are partially offset by declining realised prices and significant research investment.
Investors should monitor whether prescription growth continues exceeding reductions in average selling prices. The relationship will be particularly important as additional countries expand reimbursement and competing medicines enter the market. Strong treatment volumes remain economically valuable only when they generate sufficient margins.
The company’s capital allocation decisions also deserve attention. Manufacturing investment and acquisitions can support long-term growth, but they create financial obligations before all expected benefits become available. The acquired research portfolio must deliver enough successful medicines to justify the expenditure reflected in current earnings.
Eli Lilly’s latest results demonstrate extraordinary demand for its diabetes and obesity treatments, but the investment case is evolving beyond simple sales expansion. The company must preserve profitability while making therapies more accessible and building a more diversified pipeline. The decisive question for 2027 is whether sustained volume growth, manufacturing investment and successful drug development can generate attractive earnings after accounting for the increasingly substantial cost of growth.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
